324 Blackwell Street
Bay 12, Suite #1220
About Dermavant Sciences
Dermavant Sciences is dedicated to developing and, upon regulatory approval, commercializing innovative therapies in medical dermatology. Dermavant has four clinical-stage drugs in development: RVT-501, RVT-502, RVT-503, and RVT-201.
RVT-501 is a highly potent and selective topical phosphodiesterase-4 inhibitor currently in development for patients with mild-to-moderate atopic dermatitis. RVT-502, also known as cerdulatinib, is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor being developed as a topical therapy for a variety of serious dermatologic conditions. RVT-503 is an undisclosed preclinical asset being studied for the treatment of acne. RVT-201 is a caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines and is being developed for inflammatory skin diseases.
Founder: Vivek Ramaswamy
Executive Chair: Jackie Fouse, PhD
CMO: Jim Lee, MD, PhD
Please click here for Dermavant Sciences' pipeline.
18 articles with Dermavant Sciences
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its pivotal Phase 3 psoriasis clinical program, PSOARING, for its lead product candidate, tapinarof. Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream being developed by Dermavant for plaque psoriasis and atopic dermatitis
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to Dermavant’s Board of Directors.
3/29/2019Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller at Revance Therapeutics
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Philip M. Brown, M.D., J.D., as Chief Medical Officer.
Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit
Dermavant Sciences today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.
11/19/2018Companies bolstered their leadership with additions to boards of directors and c-suite offices.
Mr. Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry.
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
Celgene Vet Jackie Fouse Taking Over as CEO of Agios Pharmaceuticals; Companies Also Terminate Pr...
9/5/2018One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals.
Dr. Jackie Fouse to step down as Executive Chair of Dermavant
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.
Dermavant announced that President and Chief Operating Officer Vince Ippolito will present a corporate overview at the JMP Securities Life Science Conference
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
Dermavant Sciences, a company founded by biotech guru Vivek Ramaswamy, tapped former GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer.
Dermavant Sciences announced that it has expanded its pipeline by in-licensing an investigational drug for the treatment of multi-focal hyperhidrosis.